AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Leucine-rich repeat-containing G-protein coupled receptor 4

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9BXB1

UPID:

LGR4_HUMAN

Alternative names:

G-protein coupled receptor 48

Alternative UPACC:

Q9BXB1; A6NCH3; G5E9B3; Q8N537; Q9NYD1

Background:

Leucine-rich repeat-containing G-protein coupled receptor 4 (LGR4) plays a pivotal role in the canonical Wnt signaling pathway, essential for organ development including liver, kidney, and bone. Unlike typical G-protein coupled receptors, LGR4 does not activate heterotrimeric G-proteins but instead facilitates Wnt signal transduction, influencing gene expression and cellular processes.

Therapeutic significance:

LGR4's involvement in diseases like Osteoporosis and its role in bone formation and remodeling highlight its potential as a target for therapeutic intervention. Understanding the function of LGR4 could lead to novel treatments for skeletal disorders and delayed puberty, leveraging its regulatory effects on bone density and reproductive development.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.